Recombinant Human ICAM-4 Fc Chimera Protein, CF

When Recombinant Human Integrin alpha L beta 2 Protein (3868-AV) is immobilized at 1 μg/mL (100 μL/well), Recombinant Human ICAM-4 Fc Chimera (10407-IC) binds with an ED50 of 0.25-1.5 μg/mL.

2 μg/lane of Recombinant Human ICAM-4 Fc Chimera (Catalog # 10407-IC) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at kDa.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human ICAM-4 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human Integrin alpha L beta 2 (Catalog # 3868-AV) is immobilized at 1 µg/mL (100 µL/well), Recombinant Human ICAM-4 Fc Chimera (Catalog # 10407-IC) binds with an ED₅₀ of 0.25-1.5 μg/mL.
• Source: Chinese Hamster Ovary cell line, CHO-derived human ICAM-4 protein
  

  Human ICAM-4 (Ala31-Ala240) Accession # Q14773.1	DIEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: Q14773.1
• N-terminal Sequence: Ala31
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 50 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 50-60 kDa & 70-80 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 400 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human ICAM-4 Fc Chimera Protein, CF

• CD242 antigen
• CD242
• ICAM4
• ICAM-4
• intercellular adhesion molecule 4 (Landsteiner-Wiener blood group)
• intercellular adhesion molecule 4 (LW blood group)
• intercellular adhesion molecule 4
• intercellular adhesion molecule 4, Landsteiner-Wiener blood group
• Landsteiner-Wiener blood group antigen a
• Landsteiner-Wiener blood group glycoprotein
• Landsteiner-Wiener blood group
• LWLW blood group protein

Background

ICAM-4 (intercellular adhesion molecule-4), also known as CD242, is a transmembrane cell adhesion glycoprotein and a member of the immunoglobulin protein superfamily. The ICAM sub-family consists of five members, ICAM-1 through ICAM-5, and they vary in their tissue expression and number of Ig-like domains in the extracellular domain (ECD) (1). Full-length human ICAM-4 contains 2 Ig-like domains in the ECD, a single transmembrane domain and short intracellular domain. Alternative splicing of ICAM-4 results in at least one soluble form (2). The ECD of mature human ICAM-4 shares 68% and 67% amino acid sequence identity with mouse and rat ICAM-4, respectively. ICAM-4 expression is limited to erythroid and possibly placental tissue but its biological role remains poorly defined (3). ICAM-4 has been shown to bind alpha 4 beta 1 and alpha V family integrins as well as displaying broad ligand binding specificity for some beta 1, beta 2, beta 3 and beta 5 integrins (4, 5). ICAM-4 binding to endothelial alpha v beta 3 has been indicated as a factor in vaso-occlusion, particularly in sickle cell disease (6). ICAM-4 is expressed on red blood cells (RBC), erythroid precursor cells, and possibly placental tissue (3, 7). ICAM-4 has shown to bind alpha 4 beta 1 on hemopoietic cells, alpha V family integrins (avb1, avb3, and avb5) on non-hemopoietic cells as well as displaying broad ligand binding specificity for some beta 1, beta 2, beta 3 and beta 5 integrins (4, 5, 7). Studies have shown aLb2 integrin interacts through the first Ig-like domain of ICAM-4, whereas aMb2 and aXb2 integrins interact through both Ig-like domains of ICAM-4 (7). In addition, initiation of vaso-occlusion in sickle cell disease is implicated by ICAM-4 binding to endothelial alpha v beta 3 integrin (6). The ability of ICAM-4 to interact selectively with different integrins suggests its importance in RBC physiology and pathology as well as its therapeutic value.

1. Gahmberg, C.G. et al. (1997) Eur. J. Biochem. 245, 215.
2. Lee, G. et al. (2003) Blood 101:1790.
3. Southcott, M.J.G. et al. (1999) Blood 93:4425.
4. Spring, F.A. et al. (2001) Blood. 98:458.
5. Hermand, P. et al. (2003) J Biol Chem. 278:4892.
6. Kaul, D.K. et al. (2006) Am J Physiol Cell Physiol. 291:C922.
7. Ihanus, E. et al. (2007) Blood 109:802.

Bioinformatics

• Uniprot:
  • Q14773.1()